Print Page |
RSS Feeds |
Email Alerts |
IR Contacts
<< Back
Spectranetics' CLiRpath Excimer Laser Catheters Featured in the Detroit News

COLORADO SPRINGS, Colo., Feb. 3 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced the Company's CLiRpath(R) Excimer Laser Catheter was featured in the January 26 edition of The Detroit News. The article featured the treatment of peripheral vascular disease using Spectranetics' CLiRpath excimer laser catheter by Dr. Elias Kassab at Oakwood Hospital in Dearborn, Michigan, and included favorable testimonial by two patients post-procedure.

"Dr. Kassab's work at Oakwood Hospital further validates the quality-of-life improvements that may be achieved with our CLiRpath excimer laser catheters," said John G. Schulte, president and chief executive officer of Spectranetics. "The Detroit News story is the latest of several news articles featuring physicians treating peripheral vascular disease with our CLiRpath excimer laser catheters and the life-changing successful outcomes of their patients."

Commenting on his experience with CLiRpath excimer laser catheters, Dr. Kassab said, "The impact has been tremendous in terms of salvaging legs in patients with limb ischemia. Diabetic patients should be aware of warning signs of clogged arteries and alert their doctors if experiencing pain or discomfort in the legs."

Dr. Elias Kassab is Director of Cardiology Endovascular Services at Oakwood Hospital. He has performed more than 75 CLiRpath procedures and has trained other doctors in Michigan and throughout the U.S. on the procedure. Other hospitals in Michigan performing the CLiRpath procedure include Detroit Medical Center and St. John Hospital.

More information on this and other recent articles and news segments featuring Spectranetics' CLiRpath excimer laser catheters can be found on the Company's website at

CLiRpath(R) Excimer Laser Catheters are indicated for use in the endovascular treatment of symptomatic infrainguinal lower extremity vascular disease where total obstructions cannot be crossed with standard guide wires.

About Spectranetics

Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. The Company's CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary and peripheral atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of Spectranetics' FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004, the Company obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.

For further information, please contact: John Schulte, Chief Executive Officer, or Guy Childs, Chief Financial Officer, both of Spectranetics Corporation, +1-719-633-8333; or Bruce Voss or Ina McGuinness, both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100.

SOURCE Spectranetics Corporation
CONTACT: John Schulte, Chief Executive Officer,
Guy Childs, Chief Financial Officer,
both of Spectranetics Corporation,
Bruce Voss or Ina McGuinness,
both of Lippert/Heilshorn & Associates, Inc.,
Web site: